Beijing Baheal Chengchuang Pharmaceutical Research and Development Co., Ltd. is a wholly-owned subsidiary of Baheal Pharma Group. As the industrial investment platform of Baheal, Baheal Sinovate is committed to incubating original innovations that can truly optimize medical scenarios. Through allocating comprehensive industrial resources, it supports the development and breakthroughs of innovative projects to create pharmaceutical technology products and solutions with independent intellectual property rights, thereby continuously advancing the progress of China’s pharmaceutical and healthcare industry.
Baheal Pharma Group is a health industry group driven by technological innovation, with core businesses including medical innovation incubation, manufacturing and commercialization. Based on the deep insights into medical scenarios and advanced incubation mechanisms, Baheal has established a Research and Development Platform that collaborates with National Research Institutions to discover original innovations based on basic biological R&D and innovative achievements investment incubation with First-in-Class potential. Baheal Pharma Group’s listed enterprise, Baheal Medical, as an industrialization platform with innovative brand-building capabilities, aims to accelerate the introduction of medical innovations into clinical applications constantly. Currently, we have formed a diversified products portfolio in the fields of bone health, anti-organ fibrosis and brain metastases and have successfully incubated multiple category-leading brands.
